{
  "id": 17229789,
  "title": "Boehringer Ingelheim registers Phase III trial investigating verducatib in COPD",
  "url": "https://urgent.news/2026/10/30/boehringer-ingelheim-registers-phase-iii-trial-investigating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-30T13:39:50.000Z",
  "source": {
    "name": "Financial Post",
    "slug": "financial-post",
    "url": "https://financialpost.com/globe-newswire/boehringer-ingelheim-registers-phase-iii-trial-investigating-verducatib-in-copd"
  },
  "original_language": "en",
  "account": null,
  "summary": "Boehringer Ingelheim has registered a Phase III trial for its investigational oral therapy, verducatib, which aims to target DPP1 in adults with COPD. The trial, known as AIRWARD™, will evaluate the effectiveness of verducatib in individuals who continue to experience exacerbations despite standard treatment and have a blood eosinophil count below 300 cells/µL. Boehringer Ingelheim, with over 100 years of experience in respiratory medicine, is committed to addressing the needs of patients who still experience exacerbations while receiving standard care. The trial has been published on ClinicalTrials.gov under the identifier NCTXXXXXX.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}